Understanding Esketamine: A Breakthrough in Depression Treatment
Esketamine is a relatively new and innovative treatment for people struggling with treatment-resistant depression (TRD). Approved by the FDA in 2019 under the brand name Spravato, esketamine represents a significant advancement in psychiatric care. Administered as a nasal spray in a medical setting, it provides an alternative for those who haven’t found relief through traditional antidepressants



